Dogwood Therapeutics, Inc. Accrued Liabilities, Current
Dogwood Therapeutics, Inc. (DWTX) had Accrued Liabilities, Current of $2.35 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-14
- 2026-06-30: Accrued Liabilities, Current $2.35M.
- 2026-03-31: Accrued Liabilities, Current $2.35M.
- 2025-12-31: Accrued Liabilities, Current $2.24M.
- 2025-09-30: Accrued Liabilities, Current $1.96M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $2.35M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $2.35M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $2.24M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $1.96M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $1.33M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $1.38M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $1.89M 10-K · filed 2026-03-18 |
| 2024-09-30 | $878.86K 10-Q · filed 2024-11-08 |
| 2024-06-30 | $282.31K 10-Q · filed 2024-08-09 |
| 2024-03-31 | $373.32K 10-Q · filed 2024-05-10 |
| 2023-12-31 | $246.63K 10-K · filed 2025-03-31 |
| 2023-09-30 | $281.77K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $305.73K 10-Q · filed 2023-08-11 |
| 2023-03-31 | $414.20K 10-Q · filed 2023-05-12 |
| 2022-12-31 | $470.10K 10-K/A · filed 2024-03-08 |
| 2022-09-30 | $953.73K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $1.23M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $1.55M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $921.76K 10-K · filed 2023-03-14 |
| 2021-09-30 | $743.29K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $643.67K 10-Q · filed 2021-08-13 |
| 2021-03-31 | $552.63K 10-Q · filed 2021-05-14 |
| 2020-12-31 | $784.10K 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |